2 No-Brainer High-Yield Pipeline Stocks to Buy With $1,000 Right Now

Energy Transfer (ET) is presented as attractively valued at ~7.5x 2026 analyst EV/EBITDA with a 7.6% yield, ~1.7x distribution coverage and up to $5.5 billion in growth capex for projects including the Hugh Brinson and Desert Southwest pipelines to serve rising power demand from AI data centers. Western Midstream (WES) trades at ~8.5x forward EV/EBITDA with an 8.6% yield, leverage of ~2.8x, and used its balance-sheet strength to acquire Aris Water Solutions to pursue produced-water infrastructure—highlighted by a North Loving expansion and a Pathfinder pipeline with 800,000 bpd capacity expected online in Q1 2027—while cutting customer concentration with Occidental below 45%.

Analysis

Market structure: Winners are midstream operators with fee-based, take-or-pay contracts (ET, WES) plus pipeline contractors and Permian gas suppliers; losers include spot-exposed producers and legacy produced‑water transport-by-truck economics. ET's 7.5x 2026 EV/EBITDA and WES's 8.5x imply the market is pricing material execution and capex risk despite near-term demand tailwinds from AI data centers.

Competitive dynamics & supply/demand: Long-duration take‑or‑pay and Permian cost advantage shift pricing power to large midstream owners — ET’s $5.5bn growth capex and WES’s 800k bbl/day Pathfinder water capacity (online Q1 2027) lock in volumes and raise barriers to entry. Expect incremental natural gas and power demand from hyperscale data centers to tighten regional gas-offtake curves in 2026–27 rather than move national commodity prices materially.

Cross-asset & risk: Credit spreads for high-quality midstream debt should compress if projects finance on plan, but capex overruns or slower AI buildouts would widen spreads and stress distributions (coverage ratio watch: ET ~1.7x today; a fall below ~1.2x is a red flag). Options/vol: implied vol is likely cheap relative to realized event risk around 2026/27 in‑service dates — favor limited-loss long-dated calls or collars rather than naked exposure.

Catalysts, hidden dependencies & contrarian view: Key catalysts are FID/engineering updates, interconnection/customer contracts, and Q1 2027 in-service dates; regulatory/permit risk on produced water and counterparty credit (OXY still ~<45% of WES volumes post-deal) are tail hazards. Consensus underweights execution risk (capex inflation, delays) but may also be underestimating secular AI-driven baseload power demand that can re-rate assets rapidly if contracts expand; watch quarterly volume bookings and take‑or‑pay renewal cadence.

Key Decisions for Investors

• Establish a 2–3% net long position in Energy Transfer (ET) over the next 4–8 weeks, target +25–35% upside within 12–18 months if EBITDA multiple reverts toward 9–10x on successful project execution; use a hard stop-loss at -20% or if distributable cash flow coverage falls below 1.2x.
• Buy 1–2% position in Western Midstream (WES) as a yield-plus-growth play ahead of Q1 2027 in‑service dates; set target +20% in 12–18 months and trim half if leverage rises above 3.5x or if produced-water volumes from non‑Oxy customers remain <40% by next two quarterly reports.
• Deploy options to cap downside: purchase 12–18 month ET LEAPS calls (delta ~0.30–0.40) or buy a 12-month call spread to limit premium; alternatively sell covered calls on new WES shares to harvest yield while projects mature (roll monthly/quarterly to manage assignment risk).
• Run a relative-value pair: long ET (equal dollar) vs short XLE (energy ETF) 0.5–1.0% net exposure to isolate midstream take-or-pay re-rating from commodity volatility; rebalance if ET outperforms/underperforms by 15% or if natural gas front-month moves >30% intramonth.
• Monitor these triggers over the next 6–15 months and act: (a) quarterly updates confirming on‑budget capex and commercial agreements, (b) DCF coverage trends (alert if ET or WES <1.3x), and (c) any federal/state regulatory proposals on produced-water disposal within 90 days — pause accumulation if any trigger breaches occur.